Compare Cassava Sciences Inc (FLNA) vs Nasdaq100 ETF (QQQ) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

QQQ trades at $709.87, down 1.36% today amid neutral technical signals. The ETF shows mixed analyst sentiment with a 50/50 buy/sell split among covered analysts. Recent news highlights competitive dynamics with lower-fee alternatives like QQQM and the impact of SpaceX's addition to the Nasdaq-100 index. Technical indicators show the stock trading near key support at $711 with overall neutral momentum.

The outlook remains balanced with exposure to leading tech growth companies but faces headwinds from fee competition and index concentration risks. Upside potential exists through continued AI-driven growth, while downside risks include market volatility and ETF fee pressure. The neutral technical setup suggests near-term consolidation is likely.